Alkem Laboratories has successfully obtained EU GMP certification for its manufacturing facility at Baddi, India, marking a significant regulatory achievement for the pharmaceutical company. The Certificate of GMP Compliance was issued by the Department of Pharmacy (Human Medicines) – Germany following a comprehensive inspection of the facility.

Inspection Details and Certificate Validity

The German Health Authority conducted the inspection from 4th November 2025 to 10th November 2025, spanning seven days of thorough evaluation. The resulting certificate demonstrates the facility's compliance with European Good Manufacturing Practice standards.

Regulatory Compliance and Disclosure

The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows an earlier intimation dated 10th November 2025 regarding the EU GMP inspection by the German Health Authority at the Baddi facility.

Strategic Significance

The EU GMP certificate enables Alkem Laboratories to manufacture pharmaceutical products at its Baddi facility in accordance with European regulatory standards. This certification is crucial for companies seeking to supply pharmaceutical products to European markets, as it demonstrates adherence to stringent quality and manufacturing standards.

The three-year validity period provides the company with a substantial timeframe to leverage this certification for its European market operations. The company has made the disclosure available on its website in accordance with regulatory requirements under Regulation 30(8) of the SEBI LODR Regulations.

Alkem laboratories has provided an important update on its strategic acquisition as its wholly owned subsidiary Alkem Medtech Private Limited has executed the Share Purchase Agreement with selling shareholders of Occlutech Holding AG on March 6, 2026. This development represents the completion of the definitive agreement process that was previously announced.

Transaction Execution Details

Alkem Medtech Private Limited, the wholly owned Indian subsidiary of Alkem Laboratories, has successfully executed the Share Purchase Agreement with the selling shareholders of Occlutech Holding AG. This execution follows the earlier intimation provided to stock exchanges on February 13, 2026, regarding the intended acquisition.

Regulatory Compliance

The company has disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was communicated to both BSE Limited and National Stock Exchange of India Limited, ensuring full compliance with regulatory requirements.

Strategic Significance

This execution marks a crucial milestone in Alkem Laboratories' expansion strategy through its subsidiary. The acquisition of a majority stake ranging between 51% and 55% in the Switzerland-incorporated Occlutech Holding AG will provide significant operational control and strategic influence over the target entity. The transaction demonstrates the company's commitment to advancing its growth initiatives in the pharmaceutical and medical technology sectors.